308846-03-9

Usage

Physical state

Yellowish solid

Common uses

Organic synthesis, pharmaceutical research

Chemical structure

Contains a benzene ring and a dioxoisoindolin-2-yl group

Reactivity

Versatile and used as a building block for complex organic molecules

Applications

Drug development, agrochemicals, materials science

Value

Potential biological activity and synthetic versatility in medicinal and organic chemistry

Upstream product

• 136918-14-4 phthalimide 
• 69395-13-7 4-(2-hydroxyethyl)benzonitrile 
• 557-21-1 zinc(II) cyanide 
• 7501-05-5 N-(2-phenylethyl)phthalimide 
• 85-44-9 phthalic anhydride 
• 124499-18-9 2-(2-(4-bromophenyl)ethyl)isoindolin-1,3-dione 

Downstream Products

• 714568-34-0 2-[4-(4,5-dihydro-1H-imidazol-2-yl)-phenyl]-ethylamine 
• 1374416-64-4 C₃₅H₃₆N₄O₃S 
• 942613-38-9 2-{2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-ethyl}-isoindole-1,3-dione 
• 1374416-55-3 C₂₈H₂₈Cl₂N₄O₃S 
• 1374416-56-4 C₂₈H₂₈Cl₂N₄O₃S 
• 1374416-57-5 C₂₈H₂₈Cl₂N₄O₃S 
• 524743-24-6 ethyl 4-(2-phthalimidoethyl)benzoate 
• 187283-19-8 tert-butyl N-[[4-(2-aminoethyl)phenyl]methyl]carbamate 

Relevant academic research and scientific papers

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Dual Ligand-Enabled Nondirected C-H Cyanation of Arenes

Aromatic nitriles are key structural units in organic chemistry and, therefore, highly attractive targets for C-H activation. Herein, the development of an arene-limited, nondirected C-H cyanation based on the use of two cooperatively acting commercially available ligands is reported. The reaction enables the cyanation of arenes by C-H activation in the absence of directing groups and is therefore complementary to established approaches.

Quinolinyl- and phenantridinyl-acetamides as bradykinin B1 receptor antagonists

A new series of quinolinyl- and phenantridinyl-acetamides were synthesizer and evaluated against bradykinin B1 receptor. In vitro metabolic stability data were reported for the key compounds.The analgesic effect of compound 20 from the phenantridine series was proved in-vivo.

NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS

The present invention relates to new sulfonamide derivatives of formula (I), wherein R1 -R5 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these compounds, pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory conditions.

NEW PHENANTHRIDINE DERIVATIVES AS BRADYKININ ANTAGONISTS

The present invention relates to new phenanthridine derivatives of formula (I) wherein R1 is hydrogen atom or C1-C4 alkyl group; R2 is selected from (1) hydrogen atom; with the proviso that R1 and Rs